Tandem Diabetes Care Inc (TNDM)
28.59
-1.08
(-3.64%)
USD |
NASDAQ |
Nov 14, 16:00
28.58
-0.01
(-0.03%)
After-Hours: 20:00
Tandem Diabetes Care Research and Development Expense (Quarterly): 51.11M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 51.11M |
| June 30, 2024 | 49.33M |
| March 31, 2024 | 46.24M |
| December 31, 2023 | 42.60M |
| September 30, 2023 | 41.97M |
| June 30, 2023 | 42.93M |
| March 31, 2023 | 120.91M |
| December 31, 2022 | 35.58M |
| September 30, 2022 | 36.80M |
| June 30, 2022 | 33.57M |
| March 31, 2022 | 33.16M |
| December 31, 2021 | 29.49M |
| September 30, 2021 | 24.10M |
| June 30, 2021 | 20.50M |
| March 31, 2021 | 17.96M |
| December 31, 2020 | 17.38M |
| September 30, 2020 | 16.09M |
| June 30, 2020 | 15.99M |
| March 31, 2020 | 14.12M |
| December 31, 2019 | 12.57M |
| September 30, 2019 | 12.04M |
| June 30, 2019 | 11.20M |
| March 31, 2019 | 9.389M |
| December 31, 2018 | 8.797M |
| September 30, 2018 | 7.999M |
| Date | Value |
|---|---|
| June 30, 2018 | 6.456M |
| March 31, 2018 | 5.975M |
| December 31, 2017 | 5.751M |
| September 30, 2017 | 4.914M |
| June 30, 2017 | 4.866M |
| March 31, 2017 | 5.13M |
| December 31, 2016 | 4.345M |
| September 30, 2016 | 6.154M |
| June 30, 2016 | 4.142M |
| March 31, 2016 | 4.169M |
| December 31, 2015 | 4.135M |
| September 30, 2015 | 5.093M |
| June 30, 2015 | 3.873M |
| March 31, 2015 | 3.863M |
| December 31, 2014 | 3.921M |
| September 30, 2014 | 4.508M |
| June 30, 2014 | 3.699M |
| March 31, 2014 | 3.663M |
| December 31, 2013 | 3.346M |
| September 30, 2013 | 2.652M |
| June 30, 2013 | 2.759M |
| March 31, 2013 | 2.322M |
| December 31, 2012 | 1.989M |
| September 30, 2012 | 2.110M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
12.57M
Minimum
Dec 2019
120.91M
Maximum
Mar 2023
35.12M
Average
33.37M
Median
Research and Development Expense (Quarterly) Benchmarks
| Boston Scientific Corp | 407.00M |
| Masimo Corp | 48.30M |
| RxSight Inc | 8.838M |
| Perspective Therapeutics Inc | 9.275M |
| Xtant Medical Holdings Inc | 0.636M |